- Evidence of a personally signed (or legally acceptable representative) and dated
informed consent document indicating that the subject (or a legally acceptable
representative) has been informed of all pertinent aspects of the study.
- Adult (18 years old or older) men and women with confirmed diagnosis of mRCC treated
with Sutent, IFN-α or Bevacizumab + IFN ; on the selected institutions.
- Adult men or women with RCCm treated with any other medication that is not Sutent,
IFN-? or Bevacizumab + IFN.
- Adult men or women with mRCC with palliative care.
- Adult men or women with RCC without metastasis.